Drugs

Space brain and other cosmic problems demand new kinds of pharmaceutical protection.

Gene tests for antidepressants are going mainstream — and getting more confusing. Here’s a guide.

Soon, precision medicine could help you avoid expensive, risky procedures that you may not need.

There’s gold in your gut—and startups are mining it with microbiome science. The biggest hurdle? Stool doesn’t scale.

Since he was a child, James Peyer has been obsessed with stopping aging. Now he has a fund — and a plan.

After watching medical records get traded for billions of dollars, a tech entrepreneur says he can help you grab a share of the bounty.

Investors and families are counting on Onno Faber to galvanize research into neglected conditions—like the one threatening his hearing and sight.

Michael Pollan explores the neuroscience of psychedelics in this excerpt from his new book.

Halo Cures, a crowdfunding startup, will usher new drugs and devices through the rockiest stage of development.

A new study helps the case for a supplement known as NR, but it’s not yet a slam dunk.

Leave it to the Brits to invent a synthetic alcohol that gets you properly pickled and doesn’t make you feel poisoned.

But can they manufacture it at scale?

Teleported molecules, custom genomes, and other innovations that will deliver on the technology’s biggest promises.

They’re avoiding many of the substances that got earlier generations high. But are they better off?

Pot is being packaged like fine wines and sold with bold claims about physical and psychological benefits. Does science back up the marketing pitch?